Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JFL Life SciencesNSE:JFLLIFE 79 Earnings Yield (Joel Greenblatt) % is 21.55% as of Mar. 2026, which is 113% above its 10-year median of 10.12. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 79/100 and a GF Value™ of ₹42.85 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,011 Drug Manufacturers companies, JFL Life Sciences ranks better than 93.08% on this metric.
JFL Life Sciences's Enterprise Value for the quarter that ended in Mar. 2026 was ₹491 Mil.
JFL Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹106 Mil. JFL Life Sciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 21.55%.
The historical rank and industry rank for JFL Life Sciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
NSE:JFLLIFE'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.7 Med: 10.12 Max: 21.53
Current: 18.87
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of JFL Life Sciences was 21.53%. The lowest was 3.70%. And the median was 10.12%.
NSE:JFLLIFE's Earnings Yield (Joel Greenblatt) % is ranked better than 93.08% of 1011
companies
in the Drug Manufacturers industry
Industry Median: 3
vs NSE:JFLLIFE: 18.87
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. JFL Life Sciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 4.79%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
JFL Life Sciences (NSE:JFLLIFE) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
JFL Life Sciences Earnings Yield (Joel Greenblatt) % Related Terms
JFL Life Sciences Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences Earnings Yield (Joel Greenblatt) % Chart
NSE:JFLLIFE vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's Earnings Yield (Joel Greenblatt) % falls into.
JFL Life Sciences Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
JFL Life Sciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 21.55% mean?
JFL Life Sciences (NSE:JFLLIFE) has a Earnings Yield (Joel Greenblatt) % of 21.55% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on JFL Life Sciences and its competitors. This is 113% above median its historical median of 10.12. Over the past decade, JFL Life Sciences' Earnings Yield (Joel Greenblatt) % has ranged from 3.70 to 21.53. According to the industry distribution chart, JFL Life Sciences ranks #70 out of 1011 companies in the Drug Manufacturers industry, placing it in the top 6.9%.
Is JFL Life Sciences' Earnings Yield (Joel Greenblatt) % too high?
JFL Life Sciences' current Earnings Yield (Joel Greenblatt) % of 21.55% is 113% above median its 10-year median of 10.12. Over the past 10 years, this metric has ranged from a low of 3.70 to a high of 21.53. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.00. JFL Life Sciences' value of 21.55% is 618.3% above this industry median. Based on the distribution chart, JFL Life Sciences ranks #70 out of 1011 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, JFL Life Sciences has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #70 out of 1011 companies for Earnings Yield (Joel Greenblatt) %. This places JFL Life Sciences in the top 7% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.00. JFL Life Sciences' value of 21.55% is 618.3% above this benchmark. Historically, JFL Life Sciences' own Earnings Yield (Joel Greenblatt) % has ranged from 3.70 to 21.53 over the past decade. While the company's 10-year median is 10.12 vs. the industry median of 3.00, JFL Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.00, based on 1,011 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current Earnings Yield (Joel Greenblatt) % of 21.55% is 618.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current Earnings Yield (Joel Greenblatt) % is 21.55%, which is 113% above median its own 10-year median of 10.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Possible Value Trap. The stock's GF Value™ is ₹42.85, compared to a current price of ₹10.65 — trading 75.1% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 21.55%, which is 113% above median its 10-year median of 10.12 and 618.3% above the Drug Manufacturers industry median of 3.00. JFL Life Sciences' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current Earnings Yield (Joel Greenblatt) % is 21.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹10.65 is trading 75.1% below its estimated GF Value™ of ₹42.85.
GuruFocus considers JFL Life Sciences to be Possible Value Trap.
Key valuation signals for NSE:JFLLIFE:
Earnings Yield (Joel Greenblatt) %: 21.55% (113% above median its 10-year median of 10.12)
GF Value™: ₹42.85 vs. price of ₹10.65 (75.1% below fair value)
Industry Position: 618.3% above the Drug Manufacturers median (#70 of 1011)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
79GF Score
Get the complete analysis for NSE:JFLLIFE
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 
